US Patent

US11046713 — Androgen receptor modulating compounds

Composition of Matter · Assigned to Orion Oyj · Expires 2030-10-27 · 4y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds of formula (I) and their pharmaceutically acceptable salts, which are used to modulate the androgen receptor.

USPTO Abstract

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11046713
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-10-27
Drug substance claim
Yes
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.